29 related articles for article (PubMed ID: 16490252)
1. Phase I clinical trials of anticancer drugs in healthy volunteers: need for critical consideration.
Gupta P; Gupta V; Gupta YK
Indian J Pharmacol; 2012; 44(4):540-2. PubMed ID: 23087528
[No Abstract] [Full Text] [Related]
2. New considerations in the design of clinical trials for the treatment of acute leukemia.
Hourigan CS; Karp JE
Clin Investig (Lond); 2011 Apr; 1(4):509-517. PubMed ID: 23459118
[TBL] [Abstract][Full Text] [Related]
3. [Drug sensitivity of tumor cells in varieties of acute childhood leukemia].
Shman TV; Belevtsev MV; Buglova SE
Vopr Onkol; 2005; 51(5):558-62. PubMed ID: 16756010
[TBL] [Abstract][Full Text] [Related]
4. Cell-kill kinetics of several S-phase-specific drugs.
Bhuyan BK; Fraser TJ; Gray LG; Kuentzel SL; Neil GL
Cancer Res; 1973 Apr; 33(4):888-94. PubMed ID: 4735241
[No Abstract] [Full Text] [Related]
5. Clinical trials referral resource. Current clinical trials investigating 3-AP.
Low JA; Schoenfeldt M
Oncology (Williston Park); 2005 Mar; 19(3):354, 357-8. PubMed ID: 15828551
[No Abstract] [Full Text] [Related]
6. The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype.
Colado E; Alvarez-Fernández S; Maiso P; Martín-Sánchez J; Vidriales MB; Garayoa M; Ocio EM; Montero JC; Pandiella A; San Miguel JF
Haematologica; 2008 Jan; 93(1):57-66. PubMed ID: 18166786
[TBL] [Abstract][Full Text] [Related]
7. A model system for detecting drug impairment of antitumor host defenses.
Mihich E; Bross I; Mihich RM; Nichol CA
Cancer Res; 1970 May; 30(5):1376-83. PubMed ID: 5426939
[No Abstract] [Full Text] [Related]
8. Developmental clinical trials: building one step at a time.
Karp JE; Smith BD
Leuk Res; 2006 Jul; 30(7):765-6. PubMed ID: 16490252
[No Abstract] [Full Text] [Related]
9. Elacytarabine--lipid vector technology overcoming drug resistance in acute myeloid leukemia.
Burke AC; Giles FJ
Expert Opin Investig Drugs; 2011 Dec; 20(12):1707-15. PubMed ID: 22040175
[TBL] [Abstract][Full Text] [Related]
10. New approaches in acute myeloid leukemia.
Blum W; Marcucci G
Best Pract Res Clin Haematol; 2008 Mar; 21(1):29-41. PubMed ID: 18342810
[TBL] [Abstract][Full Text] [Related]
11. Can FLT3 inhibitors overcome resistance in AML?
Tam WF; Gary Gilliland D
Best Pract Res Clin Haematol; 2008 Mar; 21(1):13-20. PubMed ID: 18342808
[TBL] [Abstract][Full Text] [Related]
12. Idiopathic hyperammonemia (IHA) after dose-dense induction chemotherapy for acute myeloid leukemia: Case report and review of the literature.
Metzeler KH; Boeck S; Christ B; Hausmann A; Stemmler HJ; Parhofer KG; Ostermann H; Hiddemann W; Braess J
Leuk Res; 2009 Jul; 33(7):e69-72. PubMed ID: 19230970
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
